Search results for "Bone Neoplasm"

showing 10 items of 148 documents

Analysis of Heritability and Shared Heritability Based on Genome-Wide Association Studies for Thirteen Cancer Types

2015

BACKGROUND: Studies of related individuals have consistently demonstrated notable familial aggregation of cancer. We aim to estimate the heritability and genetic correlation attributable to the additive effects of common single-nucleotide polymorphisms (SNPs) for cancer at 13 anatomical sites.METHODS: Between 2007 and 2014, the US National Cancer Institute has generated data from genome-wide association studies (GWAS) for 49 492 cancer case patients and 34 131 control patients. We apply novel mixed model methodology (GCTA) to this GWAS data to estimate the heritability of individual cancers, as well as the proportion of heritability attributable to cigarette smoking in smoking-related cance…

MaleCancer ResearchLung NeoplasmsLymphomaGenome-wide association studyPolymorphism (computer science)NeoplasmsMedicineChronicGeneticsOsteosarcomaOncology And CarcinogenesisLeukemiaSmokingFamily aggregationSingle NucleotideMiddle AgedFamilial riskDiffuseKidney NeoplasmsLymphocyticOncologyAdult; Aged; Asian Continental Ancestry Group; Bone Neoplasms; European Continental Ancestry Group; Female; Humans; Kidney Neoplasms; Leukemia Lymphocytic Chronic B-Cell; Lung Neoplasms; Lymphoma Large B-Cell Diffuse; Male; Middle Aged; Neoplasms; Osteosarcoma; Polymorphism Single Nucleotide; Smoking; Testicular Neoplasms; Tissue Array Analysis; Urinary Bladder Neoplasms; Genetic Predisposition to Disease; Genome-Wide Association StudyFemaleLymphoma Large B-Cell DiffuseAdultAsian Continental Ancestry GroupEuropean Continental Ancestry Group/Bone NeoplasmsPolymorphism Single NucleotideGenetic correlationTesticular NeoplasmsLarge B-CellHumansGenetic Predisposition to DiseaseOncology & CarcinogenesisPolymorphismAgedbusiness.industryExtramuralB-CellCancerHeritabilityGenome-wide association studies for thirteen cancer typesmedicine.diseaseLeukemia Lymphocytic Chronic B-CellUrinary Bladder NeoplasmsTissue Array AnalysisbusinessGenome-Wide Association StudyJournal of the National Cancer Institute
researchProduct

Occupational factors and risk of adult bone sarcomas:a multicentric case-control study in Europe

2006

International audience; We investigated the association between occupational factors and risk of bone sarcoma, a rare tumor with a largely unknown aetiology. A multicentric case-control study was conducted in 7 European countries in 1995-97. Ninety-six cases aged 35-69 years with a centrally reviewed diagnosis of bone sarcoma (68 chondrosarcomas and 28 osteosarcomas) were compared to 2,632 population (68%) or colon cancer (32%) controls. Subjects were interviewed to obtain information on occupational, medical and reproductive history, smoking and alcohol consumption and selected exposures including use of pesticides. Response proportions were 90% among cases and 66% among controls. Odds rat…

MaleCancer ResearchMESH: OsteosarcomaMESH: ReproductionMESH: Occupational Exposure0302 clinical medicineMESH: Risk FactorsRisk FactorsEpidemiologyadult bone sarcomasOdds Ratio030212 general & internal medicineeducation.field_of_studyOsteosarcomaMESH: Middle AgedReproductionResearch Support Non-U.S. Gov'tSmokingMESH: ChondrosarcomaMiddle AgedMESH: Bone NeoplasmsMESH: Interviews as TopicMESH: Case-Control Studies3. Good healthEuropeMulticenter StudyOncology030220 oncology & carcinogenesisColonic NeoplasmsFemaleSarcomamulticentric case-control studyAdultmedicine.medical_specialtyMESH: SmokingAlcohol DrinkingPopulationChondrosarcomaBone NeoplasmsBone SarcomaOccupational medicineInterviews as Topic03 medical and health sciencesInternal medicineOccupational ExposuremedicineJournal ArticlewoodworkersHumansComparative StudyRisk factoreducationMESH: Colonic NeoplasmsMESH: Humansbusiness.industryCase-control studyoccupational risk factorsMESH: AdultOdds ratiopesticidesmedicine.diseaseMESH: MaleMESH: Odds RatioSurgery[SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologieCase-Control Studies[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologieMESH: EuropebusinessMESH: FemaleMESH: Alcohol Drinking
researchProduct

Development of a [177Lu]BPAMD Labeling Kit and an Automated Synthesis Module for Routine Bone Targeted Endoradiotherapy

2015

Painful bone lesions, both benign and metastatic, are often managed using conventional analgesics. However, the treatment response is not immediate and is often associated with side-effects. Radionuclide therapy is used for pain palliation in bone metastases as well as some benign neoplasms. Endoradiotherapy has direct impact on the pain-producing bone elements, and hence, response is significant, with minimal or no side-effects. A new potential compound for endoradiotherapy is [(177)Lu]BPAMD. It combines a highly affine bisphosphonate, covalently bridged with DOTA through an amide bond, with the low-energy β(-) emitting therapeutic radiolanthanide (177)Lu. For routine chemical application,…

MaleCancer ResearchTreatment responsePathologymedicine.medical_specialtymedicine.medical_treatmentPainBone NeoplasmsLutetiumBone and BonesPain palliationchemistry.chemical_compoundmedicineHumansDOTARadiology Nuclear Medicine and imagingBenign neoplasmsAgedRadioisotopesPharmacologyDiphosphonatesStaining and Labelingbusiness.industryGeneral MedicineBisphosphonateAmidesOncologychemistryBone lesionRadionuclide therapyReagent Kits DiagnosticRadiopharmaceuticalsNuclear medicinebusinessCancer Biotherapy and Radiopharmaceuticals
researchProduct

Activin A circulating levels in patients with bone metastasis from breast or prostate cancer

2006

Recent studies have highlighted that Activin A, a member of the transforming growth factor-beta (TGF-beta) superfamily, may be involved in the regulation of osteoblastic activity and in osteoclast differentiation. Therefore, we have investigated the clinical significance of its circulating levels in patients with bone metastasis. Activin A serum concentrations were determined, by a commercially available enzyme-linked immunosorbent assay kit, in 72 patients with breast cancer (BC) or prostatic cancer (PC) with (BM+) or without (BM-) bone metastases, in 15 female patients with age-related osteoporosis (OP), in 20 patients with benign prostatic hypertrophy (BPH) and in 48 registered healthy b…

MaleCancer Researchmedicine.medical_specialtyBone diseaseOsteoporosisProstatic HyperplasiaBone NeoplasmsBreast NeoplasmsActivin A; Benign prostatic hypertrophy; Bone metastasis; Breast cancer; Neoplasm; > Osteoporosis; Prostate cancer; Transforming growth factor ¦Â; Tumor markersSensitivity and SpecificityGastroenterologyProstate cancerBreast cancerBreast cancerOsteoclastInternal medicineBiomarkers TumormedicineHumansAgedAged 80 and overHematologyProstate cancerbusiness.industryOsteoporosiProstatic NeoplasmsBone metastasisCancerGeneral MedicineMiddle AgedActivin ATransforming growth factor ¦Âmedicine.diseaseBenign prostatic hypertrophyActivinsmedicine.anatomical_structureEndocrinologyOncologyBone metastasiTumor markersOsteoporosisNeoplasmFemalebusiness
researchProduct

Postoperative Radiation Therapy in Patients with Extracranial Chondrosarcoma: A Joint Study of the French Sarcoma Group and Rare Cancer Network

2020

International audience; PurposePostoperative radiation therapy (poRT) of intracranial/skull base chondrosarcomas (CHSs) is standard treatment. However, consensus is lacking for poRT in extracranial CHS (eCHS) owing to their easier resectability and intrinsic radioresistance. We assessed the practice and efficacy of poRT in eCHS.Methods and MaterialsThis multicentric retrospective study of the French Sarcoma Group/Rare Cancer Network included patients with eCHS who were operated on between 1985 and 2015. Inverse propensity score weighting (IPTW) was used to minimize poRT allocation biases.ResultsOf 182 patients, 60.4% had bone and 39.6% had soft-tissue eCHS. eCHS were of conventional (31.9%)…

MaleCancer Researchmedicine.medical_specialtyChondrosarcomaBone Neoplasmsmesenchymalbonesurvivalddc:616.0757030218 nuclear medicine & medical imagingsurgery03 medical and health sciences0302 clinical medicinePort (medical)adjuvantmedicinepostoperativeHumansRadiology Nuclear Medicine and imagingPostoperative PeriodradiotherapyRetrospective Studies[PHYS]Physics [physics]Radiationbusiness.industryadjuvant; bone; chondrosarcoma; mesenchymal; myxoid; postoperative; radioresistance; radiotherapy; soft tissue; surgery; survivalStandard treatmentIncidence (epidemiology)Hazard ratioRetrospective cohort studyMiddle Agedmedicine.diseasePrognosisConfidence interval3. Good healthradioresistanceTreatment OutcomeOncology030220 oncology & carcinogenesisFemaleRadiologySarcomaFranceChondrosarcomasoft tissuebusinessmyxoid
researchProduct

Serum follistatin in patients with prostate cancer metastatic to the bone

2010

The clinical significance of circulating fol- listatin (FLST), an inhibitor of the multifunctional cytokine activin A (Act A), was investigated in patients with prostate cancer (PCa). The serum concentrations of this molecule were determined by an enzyme-linked immunosorbent assay (ELISA) in PCa patients with (M?) or without (M0) bone metastases, in patients with benign prostate hyperplasia (BPH) and in healthy sub- jects (HS). The effectiveness of FLST in detecting PCa patients with skeletal metastases was determined by the receiver operating characteristic (ROC) curve analysis. Serum FLST was significantly higher in PCa patients than in BPH patients (P = 0.001) or HS (P = 0.011). Converse…

MaleCancer Researchmedicine.medical_specialtyFollistatinBone diseaseSettore MED/06 - Oncologia MedicaBone metastasis cancer follistatin prostate cancer transforming growth factor beta tumor markersBone Neoplasmsurologic and male genital diseasesGastroenterologySensitivity and SpecificityProstate cancerInternal medicineMedicineHumansClinical significanceAgedHematologybusiness.industryCancerBone metastasisProstatic NeoplasmsGeneral MedicineHyperplasiaMiddle AgedProstate-Specific Antigenmedicine.diseaseActivinsProstate-specific antigenEndocrinologyOncologySettore BIO/14 - Farmacologiabusiness
researchProduct

Serum interleukin-6 in patients with metastatic bone disease: correlation with cystatin C.

2008

The clinical significance of serum interleukin-6 (IL-6) and its correlation with cystatin C (Cyst C), an endogenous inhibitor of cysteine proteinase cathepsin K, was investigated by immunoassays in patients with bone metastasis from breast cancer (BCa) or prostate cancer (PCa). Additional studies were also performed in these patients to assess the effects of zoledronic acid (ZA) administration on the circulating levels of these molecules. Mean IL-6 and Cyst C serum concentrations were signifi- cantly increased in BCa patients and in patients with primary osteoporosis (PU) compared to healthy subjects (HS). However, Cyst C, but not IL-6, resulted significantly more elevated in BCa patients t…

MaleCancer Researchmedicine.medical_specialtyPathologyBone diseasemedicine.medical_treatmentBone NeoplasmsBreast NeoplasmsZoledronic AcidGastroenterologyProstate cancercancer metastatic bone disease cystatin cInternal medicineBiomarkers TumormedicineHumansCystCystatin CAgedAged 80 and overBone Density Conservation AgentsDiphosphonatesbiologyInterleukin-6business.industryImidazolesProstatic NeoplasmsCancerBone metastasisHematologyGeneral MedicineMiddle AgedProstate-Specific AntigenBisphosphonatemedicine.diseaseZoledronic acidROC CurveOncologyCystatin Cbiology.proteinOsteoporosisFemalebusinessmedicine.drug
researchProduct

68Ga-BPAMD: PET-imaging of bone metastases with a generator based positron emitter

2012

Abstract Purpose Bone metastases are a serious aggravation for patients suffering from cancer. Therefore, early recognition of bone metastases is of great interest for further treatment of patients. Bisphosphonates are widely used for scintigraphy of bone lesions with 99m Tc. Using the 68 Ge/ 68 Ga generator together with a macroyclic bisphosphonate a comparable PET-tracer comes into focus. Procedures The bisphosphonate DOTA-conjugated ligand BPAMD was labelled with 68 Ga. [ 68 Ga]BPAMD was evaluated in vitro concerning binding to hydroxyapatite and stability. The tracer's in vivo accumulation was determined on healthy rats and bone metastases bearing animals by μ-PET. Results BPAMD was lab…

MaleCancer Researchmedicine.medical_treatmentBone NeoplasmsElectronsGallium RadioisotopesScintigraphyHeterocyclic Compounds 1-RingIn vivoCell Line TumormedicineAnimalsRadiology Nuclear Medicine and imagingRadiochemistryDiphosphonatesmedicine.diagnostic_testbusiness.industryChemistryPositron emittersCancerPet imagingBisphosphonateLigand (biochemistry)medicine.diseaseRatsDurapatiteBone lesionPositron-Emission TomographyMolecular MedicineNuclear medicinebusinessNuclear Medicine and Biology
researchProduct

Deregulation of the G1 to S-phase cell cycle checkpoint is involved in the pathogenesis of human osteosarcoma.

2004

Osteosarcoma (OS) displays complex karyotypes with numerical changes as well as structural abnormalities suggesting that several oncogenes and tumor suppressor genes may be implicated in the biology of OS. The aim of our study was to investigate the possible implication of the molecular alterations of the G1 to S-phase checkpoint genes in the pathogenesis of OS. We analyzed samples from 29 patients and found molecular alterations of the RB and TP53 genes in 6 (21%) and 3 (10%) cases, respectively. Homozygous deletion of the INK4A/ARF locus and methylation of INK4A was detected in 3 (10%) and 2 (7%) cases, respectively. CDK4 and MDM2 co-amplification was observed in 1 case (3%). Cyclin D3 is…

MaleCell cycle checkpointAdolescentLocus (genetics)Bone NeoplasmsBiologyPathology and Forensic MedicineS PhasePathogenesisGene duplicationmedicineHumansCHEK1Cyclin D3ChildMolecular BiologyAgedOsteosarcomaReverse Transcriptase Polymerase Chain ReactionCell CycleAge FactorsG1 PhaseGene AmplificationCell BiologyG2-M DNA damage checkpointMiddle Agedmedicine.diseaseGenes cdcHistory 16th CenturyCancer researchOsteosarcomaFemaleChromosomes Human Pair 9Diagnostic molecular pathology : the American journal of surgical pathology, part B
researchProduct

Natural history of malignant bone disease in hepatocellular carcinoma: final results of a multicenter bone metastasis survey

2014

BackgroundBone is an uncommon site of metastasis in patients with advanced hepatocellular carcinoma (HCC). Therefore, there are few studies concerning the natural history of bone metastasis in patients with HCC.Patients and methodsData on clinicopathology, survival, skeletal-related events (SREs), and bone-directed therapies for 211 deceased HCC patients with evidence of bone metastasis were statistically analyzed.ResultsThe median age was 70 years; 172 patients were male (81.5%). The median overall survival was 19 months. The median time to the onset of bone metastasis was 13 months (22.2% at HCC diagnosis); 64.9% patients had multiple bone metastases. Spine was the most common site of bon…

MaleGenetics and Molecular Biology (all)medicine.medical_specialtyCarcinoma HepatocellularBone diseaseSettore MED/06 - Oncologia Medicamedicine.medical_treatmentScienceBone NeoplasmsGastroenterology and HepatologyBiochemistryGastroenterologyBone and BonesMetastasisInternal medicineMedicine and Health SciencesmedicineCarcinomaHumansAged; Bone Neoplasms; Bone and Bones; Carcinoma Hepatocellular; Female; Humans; Italy; Liver; Liver Neoplasms; Male; Middle Aged; Quality of Life; Survival Analysis; Biochemistry Genetics and Molecular Biology (all); Agricultural and Biological Sciences (all)Survival analysisAgedPharmacologyMultidisciplinarybusiness.industryCarcinomaLiver NeoplasmsQRBone metastasisHepatocellularBone fractureMiddle AgedBisphosphonatemedicine.diseaseSurvival Analysiszoledronic acidHepatocellular Carcinomaskeletal-related eventsSurgeryZoledronic acidOncologyItalyLiverAgricultural and Biological Sciences (all)Quality of LifeMedicineFemalebusinessResearch Articlemedicine.drug
researchProduct